I could be wrong but we are being assessed against the current standard of care. That is currently other TAVR devices. So I assume we would publish our results against the thousands of existing published results for existing on market devices. (these well documented results make up the current standard of care.)
I don’t think we actually implant other companies devices in this trial.
Not advice and DYOR.
Ann: Annual Report to shareholders, page-9
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.20 |
Change
-0.290(2.32%) |
Mkt cap ! $257.9M | |||
| Open | High | Low | Value | Volume |
| $12.49 | $12.50 | $11.80 | $396.0K | 32.70K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 923 | $11.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.20 | 1821 | 1 |
View Market Depth
| Last trade - 16.10pm 30/09/2024 (20 minute delay) ? |
| AVR (ASX) Chart |